Bulk Pharmaceutical API Sources for FLOLAN

Bulk Pharmaceutical API Sources for FLOLAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-132-470
Amadis Chemical		A833449
Finetech Industry Limited		FT-0630728
AKos Consulting & Solutions		AKOS024457370
AvaChem Scientific		61849-14-7
AvaChem Scientific		2641S
BOC Sciences		61849-14-7

FLOLAN API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for the bulk active pharmaceutical ingredient (API) of FLOLAN (epoprostenol sodium). Epoprostenol sodium is a synthetic prostacyclin analog used to treat pulmonary arterial hypertension (PAH). Key findings detail current manufacturing capabilities, patent expiries, and market dynamics influencing API availability and pricing.

What is FLOLAN (Epoprostenol Sodium)?

FLOLAN is the brand name for epoprostenol sodium, a potent vasodilator and platelet aggregation inhibitor. It is primarily indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association (NYHA) class III and IV symptoms. Epoprostenol sodium is administered intravenously, requiring continuous infusion due to its short half-life of approximately 3-5 minutes [1].

The API, epoprostenol sodium, is a complex synthetic molecule requiring specialized manufacturing processes. Its therapeutic efficacy in severe PAH necessitates a consistent and high-quality supply of the API.

Global Epoprostenol Sodium API Manufacturing Capacity

Manufacturing of epoprostenol sodium API is concentrated among a limited number of specialized pharmaceutical chemical companies. These entities possess the requisite expertise in multi-step organic synthesis and stringent quality control measures to produce APIs meeting pharmacopeial standards.

Key manufacturing regions include:

• Europe: Several European countries host API manufacturers with established production lines for complex small molecules. These manufacturers often adhere to rigorous European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) Good Manufacturing Practice (GMP) guidelines.
• North America: The United States has a presence of API manufacturers capable of producing epoprostenol sodium, often serving the domestic market and meeting FDA requirements.
• Asia: Manufacturers in India and China are increasingly participating in the global API market. While some Asian manufacturers offer competitive pricing, the ability to consistently meet the highest quality and regulatory standards for this specific API is a critical differentiator.

Current Estimated Global Production Capacity: Precise figures for dedicated epoprostenol sodium API production capacity are proprietary. However, industry estimates suggest that the existing global capacity is sufficient to meet current demand, with some incremental room for expansion. The lead time for establishing new, GMP-compliant manufacturing lines for such a complex API is substantial, typically 18-24 months.

Major API Suppliers (Indicative): While direct API sales are often B2B and not widely publicized, companies known for producing complex synthetic APIs and holding relevant DMFs (Drug Master Files) for epoprostenol sodium include:

• Specialty chemical manufacturers based in the EU.
• Select North American contract manufacturing organizations (CMOs) with advanced synthesis capabilities.
• Certain Indian API manufacturers with strong regulatory track records.

Patent Landscape and Exclusivity

The patent landscape for epoprostenol sodium itself has largely expired, allowing for generic competition. However, patents related to specific manufacturing processes, crystalline forms, or improved formulations can still provide market exclusivity for certain suppliers or product versions.

Original Compound Patents: The foundational patents covering the epoprostenol molecule have long since expired. This means the chemical entity itself is in the public domain.

Process Patents: Patents for novel or improved synthetic routes for epoprostenol sodium may exist. These patents can significantly impact the cost and efficiency of API production. A company holding a dominant process patent could control a substantial portion of the supply chain or command higher prices if their process offers significant advantages (e.g., higher yield, fewer impurities, lower environmental impact).

Formulation and Delivery Patents: While this analysis focuses on the API, it is important to note that patents protecting specific formulations (e.g., lyophilized powders for reconstitution, improved diluents) or delivery devices can extend market exclusivity for finished drug products even after API patent expiry.

Exclusivity Periods:

• Orphan Drug Exclusivity (ODE): Epoprostenol sodium is designated as an orphan drug for PAH. This designation provides 7 years of market exclusivity in the U.S. from the date of drug approval for that indication, preventing FDA approval of other applications for the same drug for the same rare disease [2]. This exclusivity is granted to the drug product, not the API itself, and is tied to the innovator company.
• Data Exclusivity: Upon approval of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), the FDA grants a period of data exclusivity that prevents the approval of generic versions based on the innovator's clinical data.

Impact of Patent Expiry: The expiry of core compound patents has paved the way for generic epoprostenol sodium products. However, the technical challenges and regulatory hurdles in manufacturing a high-quality, stable API for intravenous administration have limited the number of generic entrants compared to more common small molecules.

Market Dynamics and Supply Chain Considerations

The market for epoprostenol sodium API is characterized by specific dynamics driven by the therapeutic area, regulatory requirements, and the nature of the drug product.

Demand Drivers:

• Prevalence of PAH: While PAH is a rare disease, the increasing diagnosis rates and improved understanding of its pathophysiology contribute to demand.
• Treatment Guidelines: Epoprostenol sodium remains a treatment option for severe PAH patients, particularly those who do not respond adequately to other therapies.
• Aging Population: The incidence of cardiovascular diseases, including PAH, can increase with age.

Pricing Factors:

• Manufacturing Complexity: The multi-step synthesis and stringent purification required for epoprostenol sodium API result in higher production costs compared to simpler APIs.
• Regulatory Compliance: Maintaining GMP certification and supporting regulatory filings (e.g., DMFs) for multiple markets incurs significant expenses.
• Scale of Production: The relatively niche market for epoprostenol sodium means production runs may be smaller than for blockbuster drugs, impacting economies of scale.
• Competition: The number of qualified API suppliers influences pricing. A more consolidated supply chain can lead to higher prices.
• Quality and Purity Standards: Meeting pharmacopeial monographs (e.g., USP, EP) and customer specifications for impurities is paramount and adds to production costs.

Supply Chain Risks:

• Single-Source Dependencies: If only a few API manufacturers can meet the stringent quality and regulatory requirements, the supply chain can be vulnerable to disruptions at any single facility.
• Raw Material Availability: Sourcing specialized starting materials and reagents for complex organic synthesis can be subject to its own supply chain risks.
• Geopolitical Factors: Trade disputes, import/export restrictions, or political instability in key manufacturing regions can impact API flow.
• Regulatory Audits and Inspections: Unexpected findings during GMP audits or FDA/EMA inspections can lead to production halts or require costly remediation.
• Disposal of Waste Products: The synthesis of complex organic molecules can generate specific waste streams that require specialized and costly disposal methods, adding to overall manufacturing costs.

Contract Manufacturing Organizations (CMOs): Many pharmaceutical companies, both innovator and generic, rely on CMOs for API production. For epoprostenol sodium, the selection of a CMO requires thorough due diligence regarding their synthetic chemistry expertise, regulatory history, quality systems, and capacity for handling hazardous materials if applicable.

Key Performance Indicators (KPIs) for API Sourcing:

• API Purity and Impurity Profile: Meeting USP/EP specifications, with low levels of known and unknown impurities.
• Batch-to-Batch Consistency: Ensuring uniform quality across all manufactured lots.
• Regulatory Compliance: Successful DMF filings and positive audit outcomes from regulatory agencies.
• Lead Time: Time from order placement to API delivery, critical for inventory management.
• Cost per Kilogram: Competitive pricing without compromising quality.
• Supply Chain Resilience: Dual sourcing strategies where feasible, contingency planning for disruptions.

Future Outlook and Strategic Considerations

The future supply of epoprostenol sodium API will be shaped by ongoing regulatory developments, technological advancements in synthesis, and the evolving PAH treatment landscape.

Potential for New Entrants: While the technical barriers are high, continued demand and attractive market pricing may incentivize new, qualified API manufacturers to enter the space, particularly those with strong expertise in lyophilization and sterile API manufacturing.

Process Innovation: Research into more efficient or environmentally friendly synthetic pathways for epoprostenol sodium could reduce manufacturing costs and improve sustainability, potentially influencing future pricing and supply dynamics.

Advancements in PAH Treatment: The development of novel therapeutic agents for PAH, including oral prostacyclin analogs or alternative mechanisms of action, could impact the long-term demand for intravenous epoprostenol sodium and, consequently, its API.

Supply Chain Diversification: For pharmaceutical companies relying on epoprostenol sodium, diversifying their API supplier base, where possible and compliant with regulations, will be a critical strategy to mitigate supply chain risks. This involves identifying and qualifying at least two GMP-compliant manufacturers.

Strategic Sourcing: Given the specialized nature of epoprostenol sodium API, strategic sourcing efforts should focus on:

1. Long-term supply agreements: To secure volume and pricing stability.
2. Robust quality agreements: Clearly defining specifications, change control, and auditing rights.
3. Supplier audits: Regular and thorough assessments of manufacturing sites and quality systems.
4. Inventory management: Balancing the need for sufficient stock against the shelf-life and storage requirements of the API.

The global supply of epoprostenol sodium API is a mature but specialized market. Companies involved in its production or procurement must navigate complex manufacturing requirements, a well-defined patent expiry, and the inherent risks associated with a niche, life-saving therapy.

---

Key Takeaways

• Epoprostenol sodium API manufacturing is concentrated among a limited number of specialized global suppliers in Europe, North America, and Asia, requiring advanced synthesis and stringent quality control.
• Core compound patents for epoprostenol sodium have expired, permitting generic entry, but process patents and regulatory exclusivities for finished products can still influence market dynamics.
• The API market is driven by PAH prevalence and treatment guidelines, with pricing influenced by manufacturing complexity, regulatory adherence, and scale of production.
• Supply chain risks include single-source dependencies, raw material availability, geopolitical factors, and regulatory audit outcomes.
• Future strategies should emphasize supply chain diversification, process innovation, and robust quality and supply agreements to ensure consistent API availability.

---

Frequently Asked Questions

1. What are the primary regulatory hurdles for epoprostenol sodium API manufacturers? Manufacturers must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies like the FDA and EMA, including stringent requirements for process validation, impurity control, stability testing, and sterile handling if the API is intended for parenteral products. Filing and maintaining Drug Master Files (DMFs) in relevant jurisdictions is also a significant regulatory requirement.

2. How does the orphan drug designation for epoprostenol sodium impact API sourcing? The Orphan Drug Exclusivity (ODE) provides market exclusivity for the drug product for a period of 7 years in the U.S. This exclusivity is granted to the approved indication and does not directly prevent the manufacture or sale of the API by other entities for other potential (though unlikely) uses or for use by companies holding their own approved applications post-ODE. However, it reinforces the economic viability for the innovator and influences the competitive landscape for generic finished products.

3. What are the typical quality specifications for epoprostenol sodium API? API specifications are defined by pharmacopeial monographs (e.g., United States Pharmacopeia [USP], European Pharmacopoeia [EP]). These typically include assays for epoprostenol sodium content (e.g., not less than 98.0% and not more than 102.0% on the dried basis), limits for specific impurities (related substances), residual solvents, water content, and microbial limits. Particle size distribution and polymorphic form may also be critical depending on the downstream formulation process.

4. What is the shelf-life of epoprostenol sodium API and how does it affect inventory management? The typical shelf-life for epoprostenol sodium API, when stored under recommended conditions (e.g., refrigerated, protected from light), is generally between 2 to 5 years. This requires careful inventory management, often involving just-in-time ordering by finished product manufacturers to avoid expiry of costly API batches, balanced against the need for sufficient stock to prevent supply interruptions.

5. Are there significant differences in the quality or manufacturing processes between different epoprostenol sodium API suppliers? Yes, there can be significant differences. While all API suppliers must meet pharmacopeial standards, variations exist in the specific synthetic routes employed, the impurity profiles generated, and the purification techniques used. These differences can impact the cost of goods, environmental footprint, and potentially the stability or compatibility of the API in specific formulations. Rigorous supplier qualification and the establishment of detailed quality agreements are essential to manage these variations.

---

Citations

[1] GlaxoSmithKline. (2021). FLOLAN® (epoprostenol for injection) [Prescribing Information]. Retrieved from [Example URL of PI - Actual URL would be sourced]

[2] U.S. Food and Drug Administration. (2019). Orphan Drug Act Designation. Retrieved from [Example URL of FDA guidance - Actual URL would be sourced]